BNP Paribas Financial Markets Sells 14,993 Shares of Silicon Laboratories Inc. (NASDAQ:SLAB)

BNP Paribas Financial Markets reduced its position in shares of Silicon Laboratories Inc. (NASDAQ:SLAB - Free Report) by 61.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,225 shares of the semiconductor company's stock after selling 14,993 shares during the quarter. BNP Paribas Financial Markets' holdings in Silicon Laboratories were worth $1,146,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Silicon Laboratories in the fourth quarter worth approximately $14,252,000. Arizona State Retirement System grew its holdings in shares of Silicon Laboratories by 1.8% in the fourth quarter. Arizona State Retirement System now owns 9,360 shares of the semiconductor company's stock valued at $1,163,000 after acquiring an additional 167 shares in the last quarter. Barclays PLC grew its holdings in shares of Silicon Laboratories by 23.4% in the third quarter. Barclays PLC now owns 70,568 shares of the semiconductor company's stock valued at $8,157,000 after acquiring an additional 13,363 shares in the last quarter. Arkadios Wealth Advisors bought a new position in shares of Silicon Laboratories in the fourth quarter valued at approximately $237,000. Finally, Pacer Advisors Inc. grew its holdings in shares of Silicon Laboratories by 1.8% in the fourth quarter. Pacer Advisors Inc. now owns 4,839 shares of the semiconductor company's stock valued at $601,000 after acquiring an additional 87 shares in the last quarter.

Insiders Place Their Bets

In related news, CEO Robert Matthew Johnson sold 5,879 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $131.20, for a total value of $771,324.80. Following the sale, the chief executive officer now owns 73,688 shares in the company, valued at approximately $9,667,865.60. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christy Wyatt sold 546 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $104.45, for a total value of $57,029.70. Following the sale, the director now owns 8,492 shares in the company, valued at $886,989.40. The trade was a 6.04% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,626 shares of company stock worth $1,509,319 over the last 90 days. Corporate insiders own 1.60% of the company's stock.

Silicon Laboratories Stock Performance

NASDAQ SLAB traded down $1.32 on Monday, hitting $121.43. 265,583 shares of the stock traded hands, compared to its average volume of 337,770. The firm has a market capitalization of $3.96 billion, a price-to-earnings ratio of -20.44 and a beta of 1.36. The business's fifty day moving average is $108.77 and its two-hundred day moving average is $121.84. Silicon Laboratories Inc. has a 12 month low of $82.82 and a 12 month high of $160.00.

Silicon Laboratories (NASDAQ:SLAB - Get Free Report) last posted its earnings results on Tuesday, May 13th. The semiconductor company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $177.71 million for the quarter, compared to the consensus estimate of $177.48 million. Silicon Laboratories had a negative return on equity of 10.46% and a negative net margin of 32.69%. The business's quarterly revenue was up 67.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.92) earnings per share. Analysts expect that Silicon Laboratories Inc. will post -0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SLAB. Wall Street Zen raised Silicon Laboratories from a "sell" rating to a "hold" rating in a report on Wednesday, May 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $150.00 target price on shares of Silicon Laboratories in a report on Wednesday, May 14th. Stifel Nicolaus reduced their target price on Silicon Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Susquehanna upped their target price on Silicon Laboratories from $100.00 to $110.00 and gave the company a "neutral" rating in a report on Wednesday, May 14th. Finally, Benchmark reissued a "buy" rating and set a $160.00 price objective on shares of Silicon Laboratories in a report on Wednesday, May 14th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $126.50.

Silicon Laboratories Profile

Silicon Laboratories Inc, a fabless semiconductor company, provides various analog-intensive mixed-signal solutions in the United States, China, Taiwan, and internationally. The company's products include wireless microcontrollers and sensor products. Its products are used in various electronic products in a range of applications for the industrial Internet of Things (IoT), including industrial automation and control, smart buildings, access control, HVAC control, and industrial wearables and power tools; smart cities applications, such as smart metering, smart street lighting, renewable energy, electric vehicle supply equipment, and smart agriculture; commercial IoT applications, including smart lighting, asset tracking, electronic shelf labels, theft protection, and enterprise access points; smart home applications, comprising home automation/security systems, smart speakers, smart lighting, HVAC control, smart cameras, smart appliances, smart home sensing, smart locks, and window/blind controls; and connected health applications, including diabetes management, consumer health and fitness, elderly care, patient monitoring, and activity tracking; as well as in commercial building automation, consumer electronics, and medical instrumentation.